ARTICLE | Clinical News
Adlyxin regulatory update
August 8, 2016 7:00 AM UTC
FDA approved an NDA from Sanofi for Adlyxin lixisenatide as an adjunct to diet and exercise to treat Type II diabetes. The once-daily glucagon-like peptide-1 receptor ( GLP-1R; GLP1R) agonist is mar...